Neurooncol Pract. 2017 Dec;4(4):220-228. doi: 10.1093/nop/npw029. Epub 2016 Dec 30.
Brain tumor biobanking in the precision medicine era: building a high-quality resource for translational research in neuro-oncology.
Ostrom QT1, Devine K1, Fulop J1, Wolinsky Y1, Liao P1, Stetson L1, Couce M1, Sloan AE1, Barnholtz-Sloan JS1.
The growth of precision medicine has made access to biobanks with high-quality, well-annotated neuro-oncology biospecimens critical. Developing and maintaining neuro-oncology biobanks is best accomplished through multidisciplinary collaboration between clinicians and researchers. Balancing the needs and leveraging the skills of all stakeholders in this multidisciplinary effort is of utmost importance. Collaboration with a multidisciplinary team of clinicians, health care team members, and institutions, as well as patients and their families, is essential for access to participants in order to obtain informed consent, collect samples under strict standard operating procedures, and accurate and relevant clinical annotation. Once a neuro-oncology biobank is established, development and implementation of policies related to governance and distribution of biospecimens (both within and outside the institution) is of critical importance for sustainability. Proper implementation of a governance process helps to ensure that the biospecimens and data can be utilized in research with the largest potential benefit. New NIH and peer-reviewed journal policies related to public sharing of 'omic' data generated from stored biospecimens create new ethical challenges that must be addressed in developing informed consents, protocols, and standard operating procedures. In addition, diversification of sources of funding for the biobanks is needed for long-term sustainability.
biobanking; biospecimens; brain tumors